William Oh, MD, FACS
Assistant Clinical Professor
Surgery
School of Medicine

Education & Training

Show all (4) Hide

• Fellowship Colon and Rectal Surgery Indiana Colon and Rectal Specialists/Indiana University 2019
• Residency General Surgery University of California San Francisco 2018
• MD Medicine New York Medical College 2013
• BS Human Biology, Health, and Society Cornel University 2008

Publications (317)

Top publication keywords:
CastrationInfant, Extremely PrematureSoybean OilAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsInfant, Very Low Birth WeightAndrogen AntagonistsBilirubinProstatic NeoplasmsProstate-Specific AntigenTaxoidsProstatic Neoplasms, Castration-ResistantAntineoplastic Agents, HormonalOrchiectomyNeoplasms, Hormone-Dependent

• Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-targeted Therapy.
  American journal of clinical oncology 2024 Chakrani Z, Mellgard G, Saffran N, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh WK, Tsao CK, Patel VG
• Routine versus no assessment of gastric residual volumes in preterm infants receiving enteral feeding via intermittent feeding tubes: a randomized controlled trial.
  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2023 Williams S, Bostain R, Couch N, Kamdar T, Oh W, Thompson L, Pepe J, Yi F, Dereddy N
• Antenatal Steroids, Prophylactic Indomethacin, and the Risk of Spontaneous Intestinal Perforation.
  The Journal of pediatrics 2023 Laptook AR, Weydig H, Brion LP, Wyckoff MH, Arnautovic TI, Younge N, Oh W, Chowdhury D, Keszler M, Das A, National Institute of Child Health and Human Development Neonatal Research Network
• Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival.
  Journal of thoracic disease 2023 Liu Z, Lee K, Cohn D, Zhang M, Ai L, Li M, Zhang X, Jun T, Higashi MK, Pan Q, Oh W, Stolovitzky G, Schadt E, Wang X, Li SD
• Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer.
  The oncologist 2023 Liaw BC, Tsao CK, Seng S, Jun T, Gong Y, Galsky MD, Oh WK

Show all (312 more) Hide

• Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
  European journal of cancer (Oxford, England : 1990) 2023 Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, …
• Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
  European urology 2022 Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, …
• Effects of lipid emulsions on unbound bilirubin and response to phototherapy in preterm infants.
  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2022 Sasenick J, Kleinfeld A, Huber A, Oh W, Hegyi T, Weinberger B
• Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience.
  PloS one 2022 Guin S, Liaw BK, Jun T, Ayers K, Patel B, O'Connell T, Deitz M, Klein M, Mullaney T, Prentice T, Newman S, Fink M, Zhou X, Schadt EE, Chen R, Oh WK
• Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis.
  Discover. Oncology 2022 Qin Q, Jun T, Wang B, Patel VG, Mellgard G, Zhong X, Gogerly-Moragoda M, Parikh AB, Leiter A, Gallagher EJ, Alerasool P, Garcia P, Joshi H, Galsky M, Oh WK, Tsao CK
• Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
  Journal of cancer research and clinical oncology 2022 Mellgard G, Patel VG, Zhong X, Joshi H, Qin Q, Wang B, Parikh A, Jun T, Alerasool P, Garcia P, Gogerly-Moragoda M, Leiter A, Gallagher EJ, Oh WK, Galsky MD, Tsao CK
• Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?
  JAMA oncology 2022 Jun T, Oh WK
• Global DNA methylation of WTC prostate cancer tissues show signature differences compared to non-exposed cases.
  Carcinogenesis 2022 Yu H, Tuminello S, Alpert N, van Gerwen M, Yoo S, Mulholland DJ, Aaronson SA, Donovan M, Oh WK, Gong Y, Wang L, Zhu J, Taioli E
• Maternal Body Mass Index and Risk of Bronchopulmonary Dysplasia in Extremely Preterm Infants.
  American journal of perinatology 2022 Mayor R, Mora A, Carmona C, Du Y, Pepe J, Fritz K, Oh W
• Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.
  The oncologist 2022 Jun T, Hahn NM, Sonpavde G, Albany C, MacVicar GR, Hauke R, Fleming M, Gourdin T, Jana B, Oh WK, Taik P, Wang H, Varadarajan AR, Uzilov A, Galsky MD
• Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
  The oncologist 2022 Mack PC, Klein MI, Ayers KL, Zhou X, Guin S, Fink M, Rossi M, Ai-Kateb H, O'Connell T, Hantash FM, Oh WK, Newman S, Schadt EE, Chen R, Hirsch FR
• Extraction of Treatment Information From Electronic Health Records and Evaluation of Testosterone Recovery in Patients With Prostate Cancer.
  JCO clinical cancer informatics 2022 Guin S, Jun T, Patel VG, Ayers KL, Deitz M, Cai Y, Zhou X, Tsao CK, Oh WK, Chen R, Liaw BC
• The effects of betamethasone on the amplitude integrated EEG of infants born at 34- or 35-weeks gestation.
  Journal of perinatology : official journal of the California Perinatal Association 2022 Laptook AR, Chalak L, Pappas A, Davis A, Sanchez PJ, Van Meurs KP, Oh W, Sommers R, Shankaran S, Hensman AM, Rouse DJ, McDonald S, Das A, Goldberg RN, Ambalavanan N, Gyamfi-Bannerman C, Thom EA, …
• The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
  JNCI cancer spectrum 2022 Shah NJ, Patel VG, Zhong X, Pina L, Hawley JE, Lin E, Gartrell BA, Febles VA, Wise DR, Qin Q, Mellgard G, Joshi H, Nauseef JT, Green DA, Vlachostergios PJ, Kwon DH, Huang F, Liaw B, Tagawa S, Kantoff …
• Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
  Clinical advances in hematology & oncology : H&O 2022 Oh WK
• Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
  Clinical advances in hematology & oncology : H&O 2022 Rettig MB, Beltran H, Oh WK
• Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.
  Clinical advances in hematology & oncology : H&O 2022 Oh WK, Rettig MB
• Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
  European urology 2022 Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou …
• Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].
  European urology 2022 Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, …
• Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients.
  Frontiers in medicine 2022 Li S, Jun T, Tyler J, Schadt E, Kao YH, Wang Z, Konig MF, Bettegowda C, Vogelstein JT, Papadopoulos N, Parsons RE, Chen R, Schadt EE, Li L, Oh WK
• Reply to Carlos G. Wambier and Gerard J. Nau's Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285-93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients.
  European urology 2022 Welén K, Rosendal E, Freyhult E, Oh WK, Gisslén M, Ahlm C, Connolly AF, Överby AK, Josefsson A
• What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
  European urology 2022 Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, …
• Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.
  Breast cancer research and treatment 2022 Patel R, Li Z, Zimmerman BS, Fink MY, Wells JD, Zhou X, Ayers K, Redfern A, Newman S, Schadt E, Oh WK, Chen R, Tiersten A
• Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?
  Journal of kidney cancer and VHL 2021 Lin J, Zhang Y, Hou W, Qin Q, Galsky MD, Oh WK, Tsao CK
• A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 Pandemic.
  Quality management in health care 2021 Tremblay D, Dunn AS, Oh WK
• The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.
  Frontiers in oncology 2021 Izadmehr S, Lundon DJ, Mohamed N, Katims A, Patel V, Eilender B, Mehrazin R, Badani KK, Sfakianos JP, Tsao CK, Wiklund P, Oh WK, Cordon-Cardo C, Tewari AK, Galsky MD, Kyprianou N
• Fluid Intake in the First Week of Life and the Duration of Hemodynamically Significant Patent Ductus Arteriosus in Extremely Preterm Infants.
  American journal of perinatology 2021 Mirza H, Garcia J, Bell C, Jones K, Flynn V, Pepe J, Oh W
• PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
  Prostate cancer and prostatic diseases 2021 Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, …
• Prostate Cancer Dormancy and Reactivation in Bone Marrow.
  Journal of clinical medicine 2021 Singh DK, Patel VG, Oh WK, Aguirre-Ghiso JA
• Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
  The oncologist 2021 Ayers KL, Mullaney T, Zhou X, Liu JJ, Lee K, Ma M, Jones S, Li L, Redfern A, Jappe W, Liu Z, Goldsweig H, Yadav KK, Hahner N, Dietz M, Zimmerman M, Prentice T, Newman S, Veluswamy R, Wisnivesky J, …
• Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?
  Clinical genitourinary cancer 2021 Bikkasani K, Qin Q, Zhong X, Lin J, Galsky MD, Oh WK, Tsao CK
• Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Wang L, Sfakianos JP, Beaumont KG, Akturk G, Horowitz A, Sebra RP, Farkas AM, Gnjatic S, Hake A, Izadmehr S, Wiklund P, Oh WK, Szabo PM, Wind-Rotolo M, Unsal-Kacmaz K, Yao X, Schadt E, Sharma P, …
• Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial.
  Journal of perinatology : official journal of the California Perinatal Association 2021 Adams-Chapman I, Watterberg KL, Nolen TL, Hirsch S, Cole CA, Cotten CM, Oh W, Poindexter BB, Zaterka-Baxter KM, Das A, Lacy CB, Scorsone AM, Duncan AF, DeMauro SB, Goldstein RF, Colaizy TT, Wilson-…
• Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy.
  American journal of clinical oncology 2021 Parikh AB, Zhong X, Mellgard G, Qin Q, Patel VG, Wang B, Alerasool P, Garcia P, Leiter A, Gallagher EJ, Clinton S, Mortazavi A, Monk P, Folefac E, Yin M, Yang Y, Galsky M, Oh WK, Tsao CK
• Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data.
  Prostate cancer and prostatic diseases 2021 Martini A, Parikh AB, Sfakianos JP, Montorsi F, Galsky MD, Oh WK, Tsao CK
• Accelerating precision medicine in metastatic prostate cancer.
  Nature cancer 2020 Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, Rettig M, Schultz N, Smith M, Solit D, Sternberg C, Van …
• Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records.
  BMJ open 2020 Wang Z, Zheutlin A, Kao YH, Ayers K, Gross S, Kovatch P, Nirenberg S, Charney A, Nadkarni G, De Freitas JK, O'Reilly P, Just A, Horowitz C, Martin G, Branch A, Glicksberg BS, Charney D, Reich D, Oh WK…
• Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
  JAMA network open 2020 Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Conteduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip…
• Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
  The Journal of urology 2020 Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS
• Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
  The Journal of urology 2020 Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS
• Blood myo-inositol concentrations in preterm and term infants.
  Journal of perinatology : official journal of the California Perinatal Association 2020 Brion LP, Phelps DL, Ward RM, Nolen TL, Hallman NMK, Das A, Zaccaro DJ, Ball MB, Watterberg KL, Frantz ID, Cotten CM, Poindexter BB, Oh W, Lugo RA, Van Meurs KP, O'Shea TM, Zaterka-Baxter KM, Higgins …
• Treatment of muscle-invasive and advanced bladder cancer in 2020.
  CA: a cancer journal for clinicians 2020 Patel VG, Oh WK, Galsky MD
• Lacrimal sac adenocarcinoma managed with androgen deprivation.
  American journal of ophthalmology case reports 2020 Abramson DH, Fallon J, Biran N, Francis JH, Jaben K, Oh WK
• Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study.
  Blood 2020 Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L
• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
  European urology 2020 Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, …
• Tracheomegaly among Extremely Preterm Infants on Prolonged Mechanical Ventilation.
  The Journal of pediatrics 2019 Mirza H, Varich L, Sensakovic WF, Guruvadoo K, Royall I, Britt C, Vicenti R, Oh W
• Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants.
  Journal of perinatology : official journal of the California Perinatal Association 2019 Mirza H, Garcia J, McKinley G, Hubbard L, Sensing W, Schneider J, Oh W, Wadhawan R
• Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer.
  European urology 2019 Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD
• Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade.
  Molecular cancer research : MCR 2019 Gong Y, Wang L, Yu H, Alpert N, Cohen MD, Prophete C, Horton L, Sisco M, Park SH, Lee HW, Zelikoff J, Chen LC, Hashim D, Suarez-Farinas M, Donovan MJ, Aaronson SA, Galsky M, Zhu J, Taioli E, Oh WK
• Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
  European urology 2019 Niglio SA, Jia R, Ji J, Ruder S, Patel VG, Martini A, Sfakianos JP, Marqueen KE, Waingankar N, Mehrazin R, Wiklund P, Oh WK, Mazumdar M, Ferket BS, Galsky MD
• The evolving landscape of immunotherapy in advanced prostate cancer.
  Immunotherapy 2019 Patel VG, Oh WK
• Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial.
  JAMA 2018 Phelps DL, Watterberg KL, Nolen TL, Cole CA, Cotten CM, Oh W, Poindexter BB, Zaterka-Baxter KM, Das A, Lacy CB, Scorsone AM, Walsh MC, Bell EF, Kennedy KA, Schibler K, Sokol GM, Laughon MM, …
• The role of ketoconazole in current prostate cancer care.
  Nature reviews. Urology 2018 Patel V, Liaw B, Oh W
• Multimodal therapy in the treatment of metastatic prostate cancer: A case report.
  Urology case reports 2018 Omidele OO, Schiff HI, Oh W, Tewari A
• A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
  Journal for immunotherapy of cancer 2018 Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK
• Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy.
  Journal of clinical gastroenterology and hepatology 2018 Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch AD, Oh WK, Galsky MD, Ahmad J, Odin JA
• Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
  Urologic oncology 2018 Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP
• EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.
  Nature communications 2018 Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-…
• Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.
  The Journal of urology 2018 Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS
• Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy.
  Brachytherapy 2018 Resende Salgado L, Rhome R, Oh W, Stone N, Stock R
• Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR.
  Oncogene 2018 Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh WK, Galsky MD, Cordon-Cardo C, Zhu J
• Prostate cancer characteristics in the World Trade Center cohort, 2002-2013.
  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2018 Hashim D, Boffetta P, Galsky M, Oh W, Lucchini R, Crane M, Luft B, Moline J, Udasin I, Harrison D, Taioli E
• Effects of soybean lipid infusion on triglyceride and unbound free fatty acid levels in preterm infants.
  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2018 Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Joe Shih W, Carayannopoulos M, Oh W
• Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date.
  OncoTargets and therapy 2018 Chong JT, Oh WK, Liaw BC
• Natural History of Postnatal Cardiopulmonary Adaptation in Infants Born Extremely Preterm and Risk for Death or Bronchopulmonary Dysplasia.
  The Journal of pediatrics 2018 Mirza H, Garcia JA, Crawford E, Pepe J, Zussman M, Wadhawan R, Oh W
• Unbound bilirubin measurements by a novel probe in preterm infants.
  The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2018 Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Shih W, Carayannopoulos M, Oh W
• First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 Tsao CK, Oh WK
• Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.
  Cancer research 2018 McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, …
• Association of intralipid intake in extremely low birthweight infants with neurodevelopmental outcomes.
  Acta paediatrica (Oslo, Norway : 1992) 2018 Oh W, Przystac L, McKinley L, Tucker R, McGowan EC, Vohr BR
• Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
  European urology 2017 Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B,…
• Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers.
  Journal of oncology practice 2017 Bickell NA, Lin JJ, Abramson SR, Hoke GP, Oh W, Hall SJ, Stock R, Fei K, McAlearney AS
• Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients.
  Cancer investigation 2017 Lieberman-Cribbin W, Galsky M, Casey M, Liu B, Oh W, Flores R, Taioli E
• Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer.
  JCO clinical cancer informatics 2017 Galsky MD, Shahin M, Jia R, Shaffer DR, Gimpel-Tetra K, Tsao CK, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos JP, Acon P, Oh WK
• Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer.
  JCO clinical cancer informatics 2017 Galsky MD, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Hu L, Tsao CK, Sfakianos J, Mehrazin R, Waingankar N, Oh WK, Mazumdar M, Ferket BS
• Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey.
  Clinical genitourinary cancer 2017 Drudge-Coates L, Oh WK, Tombal B, Delacruz A, Tomlinson B, Ripley AV, Mastris K, O'Sullivan JM, Shore ND
• Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.
  Journal for immunotherapy of cancer 2017 Friedlander P, Wassmann K, Christenfeld AM, Fisher D, Kyi C, Kirkwood JM, Bhardwaj N, Oh WK
• Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
  Medical oncology (Northwood, London, England) 2017 Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS
• Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
  European urology 2017 Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP…
• Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.
  Clinical genitourinary cancer 2017 Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS
• The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
  Cancer 2017 Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML
• Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications.
  Therapeutic advances in medical oncology 2017 Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK
• Effects of Soybean Lipid Infusion on Unbound Free Fatty Acids and Unbound Bilirubin in Preterm Infants.
  The Journal of pediatrics 2017 Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Shih WJ, Carayannopoulos M, Oh W
• The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.
  Journal for immunotherapy of cancer 2016 McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL
• Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.
  Nature reviews. Clinical oncology 2016 Roubaud G, Liaw BC, Oh WK, Mulholland DJ
• Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression.
  Oncotarget 2016 Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh WK, Zhu J
• Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer.
  The oncologist 2016 Tsao CK, Sfakianos J, Liaw B, Gimpel-Tetra K, Kemeny M, Bulone L, Shahin M, Oh WK, Galsky MD
• Disease-specific classification using deconvoluted whole blood gene expression.
  Scientific reports 2016 Wang L, Oh WK, Zhu J
• Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma.
  Bladder cancer (Amsterdam, Netherlands) 2016 Leiter A, Doucette J, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh WK, Galsky MD
• The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer.
  Bladder cancer (Amsterdam, Netherlands) 2016 Casey MF, Wisnivesky J, Le VH, Sarpel U, Stensland KD, Oh WK, Galsky MD
• Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.
  European urology 2016 Tsao CK, Galsky MD, Oh WK
• Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B
• A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer.
  The Prostate 2016 Heck MM, Thalgott M, Schmid SC, Oh WK, Gong Y, Wang L, Zhu J, Seitz AK, Porst D, Höppner M, Retz M, Gschwend JE, Nawroth R
• Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition.
  European urology 2016 Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD
• Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants.
  Pediatric research 2016 Phelps DL, Ward RM, Williams RL, Nolen TL, Watterberg KL, Oh W, Goedecke M, Ehrenkranz RA, Fennell T, Poindexter BB, Cotten CM, Hallman M, Frantz ID, Faix RG, Zaterka-Baxter KM, Das A, Ball MB, Lacy …
• Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion.
  Anti-cancer drugs 2016 Kim SS, Isola LM, Oh WK
• Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, Wisnivesky JP
• Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants.
  Archives of disease in childhood. Fetal and neonatal edition 2016 Mirza H, Laptook AR, Oh W, Vohr BR, Stoll BJ, Kandefer S, Stonestreet BS, Generic Database Subcommittee of the NICHD Neonatal Research Network
• Effects of Placental Transfusion on Neonatal and 18 Month Outcomes in Preterm Infants: A Randomized Controlled Trial.
  The Journal of pediatrics 2015 Mercer JS, Erickson-Owens DA, Vohr BR, Tucker RJ, Parker AB, Oh W, Padbury JF
• Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells.
  Journal of visualized experiments : JoVE 2015 Williams ES, Rodriguez-Bravo V, Rodriquez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J
• Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.
  Cancer chemotherapy and pharmacology 2015 Galsky MD, Hahn NM, Wong B, Lee KM, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao CK, Oh WK
• A robust blood gene expression-based prognostic model for castration-resistant prostate cancer.
  BMC medicine 2015 Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK
• Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.
  Frontiers in oncology 2015 Shevach J, Gallagher EJ, Kochukoshy T, Gresia V, Brar M, Galsky MD, Oh WK
• Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?
  Nature reviews. Clinical oncology 2015 Liaw BC, Oh WK
• Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.
  Current urology reports 2015 Liaw BC, Shevach J, Oh WK
• Clinical trial awareness: Changes over time and sociodemographic disparities.
  Clinical trials (London, England) 2015 Leiter A, Diefenbach MA, Doucette J, Oh WK, Galsky MD
• Geographic accessibility to clinical trials for advanced cancer in the United States.
  JAMA internal medicine 2015 Galsky MD, Stensland KD, McBride RB, Latif A, Moshier E, Oh WK, Wisnivesky J
• Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.
  The Journal of urology 2015 Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK
• The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care.
  The Journal of urology 2015 Casey MF, Gross T, Wisnivesky J, Stensland KD, Oh WK, Galsky MD
• Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
  The Prostate 2015 Gong Y, Chippada-Venkata UD, Galsky MD, Huang J, Oh WK
• Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
  Investigational new drugs 2015 Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G
• Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).
  BJU international 2014 Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ
• A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
  Clinical genitourinary cancer 2014 Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME
• Use of crowdsourcing for cancer clinical trial development.
  Journal of the National Cancer Institute 2014 Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh WK, Galsky MD
• Adult cancer clinical trials that fail to complete: an epidemic?
  Journal of the National Cancer Institute 2014 Stensland KD, McBride RB, Latif A, Wisnivesky J, Hendricks R, Roper N, Boffetta P, Hall SJ, Oh WK, Galsky MD
• Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
  The oncologist 2014 Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD
• Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
  Cancer chemotherapy and pharmacology 2014 Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh WK
• Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression.
  Cancers 2014 Gong Y, Chippada-Venkata UD, Oh WK
• Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics.
  Cancer 2014 Galsky MD, Oh WK
• The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer.
  Therapeutic advances in urology 2014 Tsao CK, Cutting E, Martin J, Oh WK
• The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions.
  Asian journal of andrology 2014 Yu EY, Oh WK
• Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P
• T2 muscle-invasive bladder cancer.
  Seminars in oncology 2014 Tsao CK, Small A, Hall S, Oh WK, Galsky MD, Buckstein M, Stock R, Ali G, Morris GJ
• Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.
  The Journal of investigative dermatology 2014 Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui…
• Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials.
  Critical reviews in oncology/hematology 2014 Morgan CJ, Oh WK, Naik G, Galsky MD, Sonpavde G
• Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
  European urology 2014 Tsao CK, Galsky MD, Oh WK
• Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
  Cancer 2013 Doctor SM, Tsao CK, Godbold JH, Galsky MD, Oh WK
• Adverse event reporting in cancer clinical trial publications.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, Oh WK, Galsky MD
• Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
  International journal of oncology 2013 Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, …
• TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression.
  PloS one 2013 Gong Y, Scott E, Lu R, Xu Y, Oh WK, Yu Q
• Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
  Urologic oncology 2013 Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A
• Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants.
  The Journal of pediatrics 2013 Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, Oh W, Shankaran S, Tyson JE, Wright LL, Poole WK, Das A, Stoll BJ, Fanaroff AA, Korones SB, Ehrenkranz RA, Stevenson DK, Peralta-Carcelen M, …
• Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.
  Targeted oncology 2013 Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD
• Tumour angiogenesis: an elusive target in castration-resistant prostate cancer.
  The Lancet. Oncology 2013 Galsky MD, Oh WK
• Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
  Cancer 2013 Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A
• Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
  Cancer 2013 Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A
• Metabolic complications with the use of mTOR inhibitors for cancer therapy.
  Cancer treatment reviews 2013 Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD
• The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
  Clinical genitourinary cancer 2013 Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD
• Castration-resistant prostate cancer: AUA Guideline.
  The Journal of urology 2013 Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS
• New paradigms in microtubule-mediated endocrine signaling in prostate cancer.
  Molecular cancer therapeutics 2013 Mistry SJ, Oh WK
• Metabolic and toxicological considerations of newly approved prostate cancer drugs.
  Expert opinion on drug metabolism & toxicology 2013 Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK
• Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration.
  The Journal of pediatrics 2013 Mirza H, Oh W, Laptook A, Vohr B, Tucker R, Stonestreet BS
• Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
  Urologic oncology 2013 Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A
• Vitamin A supplementation in extremely low-birth-weight infants: subgroup analysis in small-for-gestational-age infants.
  American journal of perinatology 2013 Londhe VA, Nolen TL, Das A, Higgins RD, Tyson JE, Oh W, Devaskar SU, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne
• Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.
  World journal of urology 2012 Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD
• Emerging personalized approaches for the management of advanced urothelial carcinoma.
  Expert review of anticancer therapy 2012 Tsao CK, Gartrell BA, Oh WK, Galsky MD
• Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012 Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD
• Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
  Journal of the National Cancer Institute 2012 Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD
• A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.
  The Lancet. Oncology 2012 Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK
• Urological cancer: Enzalutamide in metastatic CRPC-old dog, new tricks.
  Nature reviews. Clinical oncology 2012 Tsao CK, Oh WK
• Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
  BJU international 2012 Tsao CK, Galsky MD, Small AC, Yee T, Oh WK
• Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
  BJU international 2012 Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME
• Atypical metastases from prostate cancer: 10-year experience at a single institution.
  AJR. American journal of roentgenology 2012 Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH
• Bevacizumab treatment of prostate cancer.
  Expert opinion on biological therapy 2012 Small AC, Oh WK
• Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy.
  Cancer 2012 Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD
• Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age.
  Archives of disease in childhood. Fetal and neonatal edition 2012 Wadhawan R, Oh W, Vohr BR, Saha S, Das A, Bell EF, Laptook A, Shankaran S, Stoll BJ, Walsh MC, Higgins R
• Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis.
  Cancer treatment reviews 2012 Sivendran S, Liu Z, Portas LJ, Yu M, Hahn N, Sonpavde G, Oh WK, Galsky MD
• Trends in the use of cytoreductive nephrectomy in the United States.
  Clinical genitourinary cancer 2012 Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD
• Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States.
  World journal of urology 2012 Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold J, Sonpavde G, Palese MA, Hall SJ, Oh WK, Galsky MD
• The emerging role of circulating tumor cell detection in genitourinary cancer.
  The Journal of urology 2012 Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD
• Overcoming castration resistance in prostate cancer.
  Current opinion in urology 2012 Tsao CK, Small AC, Galsky MD, Oh WK
• Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
  CA: a cancer journal for clinicians 2012 Galsky MD, Small AC, Tsao CK, Oh WK
• Hemodynamic effects of delayed cord clamping in premature infants.
  Pediatrics 2012 Sommers R, Stonestreet BS, Oh W, Laptook A, Yanowitz TD, Raker C, Mercer J
• Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
  Cancer 2012 Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK
• The effects of aggressive vs. conservative phototherapy on the brainstem auditory evoked responses of extremely-low-birth-weight infants.
  Pediatric research 2012 Lasky RE, Church MW, Orlando MS, Morris BH, Parikh NA, Tyson JE, McDavid GE, Oh W, Stevenson DK, Van Meurs KP, Guillet R, Phelps DL
• Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
  Clinical genitourinary cancer 2011 Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD
• Secondary hormonal therapy in men with castration-resistant prostate cancer.
  Clinical genitourinary cancer 2011 Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME
• The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.
  Cancer prevention research (Philadelphia, Pa.) 2011 Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GS, Kantoff PW
• Cytokines and neurodevelopmental outcomes in extremely low birth weight infants.
  The Journal of pediatrics 2011 Carlo WA, McDonald SA, Tyson JE, Stoll BJ, Ehrenkranz RA, Shankaran S, Goldberg RN, Das A, Schendel D, Thorsen P, Skogstrand K, Hougaard DM, Oh W, Laptook AR, Duara S, Fanaroff AA, Donovan EF, Korones…
• Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
  Urology 2011 Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW
• Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.
  Clinical genitourinary cancer 2011 Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF
• Early nutrition mediates the influence of severity of illness on extremely LBW infants.
  Pediatric research 2011 Ehrenkranz RA, Das A, Wrage LA, Poindexter BB, Higgins RD, Stoll BJ, Oh W, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Ne
• Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer.
  Clinical Medicine Insights. Oncology 2011 Tsao CK, Seng S, Oh WK, Galsky MD
• SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW
• Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J
• PC3 is a cell line characteristic of prostatic small cell carcinoma.
  The Prostate 2011 Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J
• Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.
  BJU international 2011 Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK
• Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.
  Cancer prevention research (Philadelphia, Pa.) 2011 Pomerantz MM, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML
• A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy.
  The Lancet. Oncology 2011 Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J
• Neurodevelopmental outcomes of triplets or higher-order extremely low birth weight infants.
  Pediatrics 2011 Wadhawan R, Oh W, Vohr BR, Wrage L, Das A, Bell EF, Laptook AR, Shankaran S, Stoll BJ, Walsh MC, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development Neonatal …
• Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants?
  Acta paediatrica (Oslo, Norway : 1992) 2011 Hintz SR, Stevenson DK, Yao Q, Wong RJ, Das A, Van Meurs KP, Morris BH, Tyson JE, Oh W, Poole WK, Phelps DL, McDavid GE, Grisby C, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health…
• Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes.
  The Journal of pediatrics 2011 Woo HC, Lizarda A, Tucker R, Mitchell ML, Vohr B, Oh W, Phornphutkul C
• Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.
  BJU international 2011 Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM
• Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Sun T, Mary LG, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, Kantoff PW
• Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article.
  Journal of neurosurgery. Spine 2010 Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S
• Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy.
  Asian journal of andrology 2010 Tsao CK, Oh WK
• Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.
  PLoS genetics 2010 Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, …
• Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.
  Cancer 2010 Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK
• Cancer therapy from bench to bedside.
  The Mount Sinai journal of medicine, New York 2010 Oh WK, Burakoff SJ
• Genome-wide association study of prostate cancer mortality.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010 Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML
• Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.
  Urologic oncology 2010 Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK
• Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients.
  Cancer 2010 Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A
• Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW
• Cabazitaxel.
  Nature reviews. Drug discovery 2010 Galsky MD, Dritselis A, Kirkpatrick P, Oh WK
• Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy.
  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2010 Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, Freedman ML
• A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
  Investigational new drugs 2010 Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G
• Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
  Urologic oncology 2010 Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK
• Castration-resistant prostate cancer: new science and therapeutic prospects.
  Therapeutic advances in medical oncology 2010 Bellmunt J, Oh WK
• Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
  BJU international 2010 Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S
• Dilemmas and controversies in the management of prostate cancer continue to present a vexing challenge to physicians and patients dealing with the disease. Preface.
  The Urologic clinics of North America 2010 Oh WK, Hu JC
• Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?
  Urology 2009 Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL
• Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP
• Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
  BJU international 2009 Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK
• Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
  BJU international 2009 Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE
• Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, …
• Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
  Clinical genitourinary cancer 2009 Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK
• The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels.
  Clinical genitourinary cancer 2009 Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ
• Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report.
  Cases journal 2009 Jacobsen E, Chen JH, Schurko B, Benson C, Oh WK
• Functional enhancers at the gene-poor 8q24 cancer-linked locus.
  PLoS genetics 2009 Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA
• Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
  Current medical research and opinion 2009 Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK
• Evaluation of the 8q24 prostate cancer risk locus and MYC expression.
  Cancer research 2009 Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, …
• Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW
• Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML
• Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
  IDrugs : the investigational drugs journal 2009 Priolo C, Oh WK, Loda M
• Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
  Cancer 2009 Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK
• Twin gestation and neurodevelopmental outcome in extremely low birth weight infants.
  Pediatrics 2009 Wadhawan R, Oh W, Perritt RL, McDonald SA, Das A, Poole WK, Vohr BR, Higgins RD
• Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
  Clinical genitourinary cancer 2009 Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI
• Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
  Urology 2008 Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK
• What is the current status of second-line chemotherapy for castration-resistant prostate cancer?
  Nature clinical practice. Urology 2008 Rosenberg JE, Oh WK
• CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers.
  Human pathology 2008 Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J
• Relationship between serum adiponectin and prostate cancer grade.
  The Prostate 2008 Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C
• Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer.
  Nature clinical practice. Oncology 2008 Schurko B, Oh WK
• Association between urinary lactate to creatinine ratio and neurodevelopmental outcome in term infants with hypoxic-ischemic encephalopathy.
  The Journal of pediatrics 2008 Oh W, Perritt R, Shankaran S, Merritts M, Donovan EF, Ehrenkranz RA, O'Shea TM, Tyson JE, Laptook AR, Das A, Higgins RD
• A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
  BJU international 2008 Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP
• Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
  Cancer 2008 Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK
• Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M
• A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
  Cancer 2008 Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK, Prostate Cancer Clinical Trials Consortium
• Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
  BJU international 2008 Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK
• Use of androgen deprivation therapy for metastatic prostate cancer in older men.
  BJU international 2008 Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR
• Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
  Cancer 2007 Xie W, Nakabayashi M, Regan MM, Oh WK
• Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
  Journal of immunotherapy (Hagerstown, Md. : 1997) 2007 Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM
• Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ
• Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
  Urology 2007 Daskivich TJ, Regan MM, Oh WK
• Human milk intake and retinopathy of prematurity in extremely low birth weight infants.
  Pediatrics 2007 Heller CD, O'Shea M, Yao Q, Langer J, Ehrenkranz RA, Phelps DL, Poole WK, Stoll B, Duara S, Oh W, Lemons J, Poindexter B, NICHD Neonatal Research Network
• Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
  The Journal of urology 2007 Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK
• Timing of umbilical cord clamping at birth in full-term infants.
  JAMA 2007 Oh W
• The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
  Cancer 2007 Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS
• Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
  Cancer journal (Sudbury, Mass.) 2007 Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK
• Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
  Cancer 2007 Oh WK, Tay MH, Huang J
• Trends in neonatal morbidity and mortality for very low birthweight infants.
  American journal of obstetrics and gynecology 2007 Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, Bauer CR, Donovan EF, Korones SB, Laptook AR, Lemons JA, Oh W, Papile LA, Shankaran S, Stevenson DK, Tyson JE, Poole WK, NICHD …
• Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice.
  The Journal of pediatrics 2007 Clyman RI, Saha S, Jobe A, Oh W
• Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.
  The Journal of urology 2006 Daskivich TJ, Regan MM, Oh WK
• Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer.
  Urologic oncology 2006 Nakabayashi M, Beard C, Kelly SM, Carr-Locke DL, Oh WK
• The medical management of prostate cancer: a multidisciplinary team approach.
  BJU international 2006 Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM
• Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
  Cancer 2006 Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK
• Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
  Cancer 2006 Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR
• Carboplatin for stage I seminoma.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Gilligan T, Oh WK, Kantoff PW
• Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW
• Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Nakabayashi M, Bartlett RA, Oh WK
• Development of an integrated prostate cancer research information system.
  Clinical genitourinary cancer 2006 Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, …
• Oral probiotics prevent necrotizing enterocolitis.
  The Journal of pediatrics 2006 Lin HC, Su BH, Oh W
• Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
  Urology 2006 Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW
• Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
  Urology 2006 Daskivich TJ, Oh WK
• Recent progress in hormonal therapy for advanced prostate cancer.
  Current opinion in urology 2006 Daskivich TJ, Oh WK
• Chemotherapy for high-risk localized prostate cancer.
  BJU international 2006 Nakabayashi M, Oh WK
• Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: a randomized, controlled trial.
  Pediatrics 2006 Mercer JS, Vohr BR, McGrath MM, Padbury JF, Wallach M, Oh W
• A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
  Cancer 2006 Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ
• Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2006 Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub T, George D
• Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months.
  Pediatrics 2006 Benjamin DK, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, Duara S, Poole K, Laptook A, Goldberg R, National Institute of Child Health and Human Development Neonatal Research Network
• Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants.
  The Journal of pediatrics 2005 Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL, Neonatal Research Network
• Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy.
  The New England journal of medicine 2005 Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA…
• Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
  BJU international 2005 Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK
• High-risk localized prostate cancer: integrating chemotherapy.
  The oncologist 2005 Oh WK
• Prolonged hospital stay for extremely premature infants: risk factors, center differences, and the impact of mortality on selecting a best-performing center.
  Journal of perinatology : official journal of the California Perinatal Association 2005 Cotten CM, Oh W, McDonald S, Carlo W, Fanaroff AA, Duara S, Stoll B, Laptook A, Poole K, Wright LL, Goldberg RN, NICHD Neonatal Research Network
• Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK
• Inhaled nitric oxide for premature infants with severe respiratory failure.
  The New England journal of medicine 2005 Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook AR, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, …
• Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003.
  The Pediatric infectious disease journal 2005 Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, Laptook A, Walsh M, Oh W, Hale E, National Institute of Child Health and Human Development
• Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.
  Clinical prostate cancer 2005 Oh WK, George DJ, Tay MH
• Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK
• A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW
• Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants.
  Pediatrics 2005 Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, Oh W
• Prevention of intraventricular hemorrhage by indomethacin in male preterm infants.
  The Journal of pediatrics 2004 Ment LR, Vohr BR, Makuch RW, Westerveld M, Katz KH, Schneider KC, Duncan CC, Ehrenkranz R, Oh W, Philip AG, Scott DT, Allan WC
• An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer.
  The Journal of urology 2004 Oh WK
• Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.
  The Journal of urology 2004 Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW
• Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer.
  Current treatment options in oncology 2004 Nakabayashi M, Oh WK
• Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.
  Cancer 2004 Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW
• A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.
  Urologic oncology 2004 Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM
• Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ
• Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer.
  Clinical prostate cancer 2004 Abe M, Manola JB, Oh WK, Parslow DL, George DJ, Austin CL, Kantoff PW
• Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants.
  Pediatrics 2004 Poindexter BB, Ehrenkranz RA, Stoll BJ, Wright LL, Poole WK, Oh W, Bauer CR, Papile LA, Tyson JE, Carlo WA, Laptook AR, Narendran V, Stevenson DK, Fanaroff AA, Korones SB, Shankaran S, Finer NN, …
• To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants.
  Pediatrics 2004 Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK
• A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2004 Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G
• Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.
  Urology 2004 George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ
• A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
  Cancer 2003 Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B 99813
• The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.
  The Journal of urology 2003 Oh WK
• Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment.
  The Journal of urology 2003 Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW
• Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants.
  Pediatrics 2003 Oh W, Tyson JE, Fanaroff AA, Vohr BR, Perritt R, Stoll BJ, Ehrenkranz RA, Carlo WA, Shankaran S, Poole K, Wright LL, National Institute of Child Health and Human Development Neonatal Research Network
• Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results.
  The Journal of urology 2003 Leibowitz SB, Oh WK
• Immediate and delayed cord clamping in infants born between 24 and 32 weeks: a pilot randomized controlled trial.
  Journal of perinatology : official journal of the California Perinatal Association 2003 Mercer JS, McGrath MM, Hensman A, Silver H, Oh W
• Does labor influence neonatal and neurodevelopmental outcomes of extremely-low-birth-weight infants who are born by cesarean delivery?
  American journal of obstetrics and gynecology 2003 Wadhawan R, Vohr BR, Fanaroff AA, Perritt RL, Duara S, Stoll BJ, Goldberg R, Laptook A, Poole K, Wright LL, Oh W
• Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update.
  Urology 2003 Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR
• Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up.
  Urology 2003 Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW
• Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
  American journal of clinical oncology 2003 Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW
• Male patients with diagnoses of both breast cancer and prostate cancer.
  The breast journal 2003 Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK
• Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints.
  Urologic oncology 2003 Oh WK
• Neoadjuvant therapy for high-risk localized prostate cancer.
  Current oncology reports 2003 Yu EY, Oh WK
• Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma.
  Cancer 2003 Oh WK, Tully P, Kantoff PW, Regan MM
• Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants.
  The American journal of clinical nutrition 2003 Poindexter BB, Ehrenkranz RA, Stoll BJ, Koch MA, Wright LL, Oh W, Papile LA, Bauer CR, Carlo WA, Donovan EF, Fanaroff AA, Korones SB, Laptook AR, Shankaran S, Stevenson DK, Tyson JE, Lemons JA, …
• Transitional cell carcinoma of the upper uroepithelial tract.
  Clinical advances in hematology & oncology : H&O 2003 Michaelson MD, Kaufman DS, Oh WK
• Complementary and alternative therapies in prostate cancer.
  Seminars in oncology 2002 Oh WK, Small EJ
• Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants.
  The Journal of pediatrics 2002 Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll B
• Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer.
  Urology 2002 Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C, Second …
• Secondary hormonal therapies in the treatment of prostate cancer.
  Urology 2002 OH WK
• The evolving role of estrogen therapy in prostate cancer.
  Clinical prostate cancer 2002 Oh WK
• Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network.
  Pediatrics 2002 Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK
• Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants.
  Pediatrics 2002 Shankaran S, Laptook A, Wright LL, Ehrenkranz RA, Donovan EF, Fanaroff AA, Stark AR, Tyson JE, Poole K, Carlo WA, Lemons JA, Oh W, Stoll BJ, Papile LA, Bauer CR, Stevenson DK, Korones SB, McDonald S
• Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants.
  The New England journal of medicine 2002 Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK
• Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
  Cancer 2002 D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW
• Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure.
  American journal of obstetrics and gynecology 2002 Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA, Oh W, Verter J
• Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants.
  The Journal of pediatrics 2002 Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B
• PC-SPES and prostate cancer.
  The Urologic clinics of North America 2002 Oh WK, Small EJ
• Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases.
  Cancer 2002 Oh WK, George DJ, Kantoff PW
• A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients.
  Cancer investigation 2002 Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MR